Summary

for people ages 18-120 (full criteria)
at La Jolla, California and other locations
study started
estimated completion:

Description

Summary

RATIONALE: Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride.

PURPOSE: This trial studies the validation of a cancer questionnaire for skin toxicities in patients with colorectal or lung cancer receiving cetuximab, panitumumab, or erlotinib hydrochloride.

Official Title

S1013: A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18(FACT-EGFRI 18) Questionnaire for EGFRI-Induced Skin Toxicities

Details

OBJECTIVES:

Primary

  • To establish psychometric properties for the Functional Assessment of Cancer Therapy Epidermal Growth Factor Receptor Inhibitor (FACT-EGFRI 18) module (based on criterion validity, known group's validity, internal consistency reliability, and responsiveness to change) as a patient-reported outcome (PRO) measure of EGFRI-induced skin-related toxicity.

Secondary

  • To document minimally important differences over time for the FACT-EGFRI 18 by comparing mean changes in this PRO measure to the patient's direct assessment of change using two anchor items (change in skin condition severity and impact).
  • To examine the association between toxicity profiles (severity and time to onset), and treatment profiles (e.g., delays and discontinuation) and the FACT-EGFRI 18 scores.
  • To assess degree of concordance between FACT-EGFRI 18 ratings and study site physician CTCAE Version 4.0 EGFRI-Induced Dermatologic Toxicity Grading Assessment ratings.
  • To evaluate feasibility outcomes.

OUTLINE: This is a multicenter study.

Patients complete the S1013 Functional Assessment of Cancer Therapy Epidermal Growth Factor Receptor Inhibitor (FACT-EGFRI 18) at baseline and prior to beginning therapy and clinical assessment. Patients also complete FACT-EGFRI 18 and the Changes in Skin Symptoms on days 1*, 8**, 15, 22, 29, 36, 43, 71, 99, and 127. Patients who do not develop any grade of papulopustular rash within 42 days are removed from study.

Investigators performing the patients' clinical assessment complete the EGFRI-Induced Dermatologic Toxicity Grading Assessment on days 1, 8, 15, 22, 29, 36, 43, 71, 99, and 127, and the Treatment Form assessment on days 22, 43, 71, 99, and 127. Nurses or clinical trial administrators (CRA) also complete the S1013 Cover Sheet for Patient Complete Questionnaires accompanying the FACT-EGFRI 18 patients' questionnaires at each schedule assessment.

NOTE: *Patients start EGFRI therapy.

NOTE: **Change in Skin Symptoms questionnaire starts on Day 8.

Keywords

Colorectal Cancer Dermatologic Complications Lung Cancer Therapy-related Toxicity stage I colon cancer stage IIA colon cancer stage IIB colon cancer stage IIC colon cancer stage IIIA colon cancer stage IIIB colon cancer stage IIIC colon cancer stage IVA colon cancer stage IVB colon cancer stage I rectal cancer stage IIA rectal cancer stage IIB rectal cancer stage IIC rectal cancer stage IIIA rectal cancer stage IIIB rectal cancer stage IIIC rectal cancer stage IVA rectal cancer stage IVB rectal cancer stage IA non-small cell lung cancer stage IB non-small cell lung cancer stage IIA non-small cell lung cancer stage IIB non-small cell lung cancer stage IIIA non-small cell lung cancer stage IIIB non-small cell lung cancer stage IV non-small cell lung cancer extensive stage small cell lung cancer limited stage small cell lung cancer recurrent small cell lung cancer recurrent colon cancer recurrent rectal cancer recurrent non-small cell lung cancer Lung Neoplasms Colorectal Neoplasms Erlotinib Hydrochloride assessment of therapy complications psychosocial assessment and care quality-of-life assessment

Eligibility

For people ages 18-120

DISEASE CHARACTERISTICS:

  • Patients must have a diagnosis of colorectal or lung cancer and be planning to receive one of the following epidermal growth factor receptor (HER1/EGFR) inhibitor therapies listed below for at least 6 weeks:
  • Cetuximab 400 mg/m² loading dose, 250 mg/m² weekly
  • Cetuximab 500 mg/m² every 2 weeks
  • Panitumumab 6 mg/kg every 2 weeks
  • Erlotinib hydrochloride 100-150 mg daily
  • Other HER1/EGFR inhibitor therapies, schedules, or doses of the above listed agents are not allowed
  • Concurrent chemotherapy and other anti-cancer therapies (such as carboplatin,paclitaxel, and bevacizumab) are allowed EXCEPT for the following chemotherapeutic agents that are known to cause skin rash that could interfere with EGFRI-induced skin toxicity assessment: gemcitabine, capecitabine, and topical fluorouracil (Efudex™, Fluoroplex™, Carac™)
  • Patients must have completed the baseline S1013 Functional Assessment of Cancer Therapy- (FACT) EGFRI 18 within 7 days prior to registration

PATIENT CHARACTERISTICS:

  • Patients must have a Zubrod performance status of 0-2
  • Patients must not have any of the following serious concomitant skin disorders that,in the investigator's opinion, could interfere with assessment of epidermal growth factor receptor inhibitor (EGFRI)-induced skin toxicity: atopic dermatitis [eczema];contact dermatitis; psoriasis; rosacea; severe photosensitivity; scleroderma;steroid-induced acne; or xerosis
  • Patients must be able to complete questionnaires in English

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • Patients may have had prior epidermal growth factor receptor (HER1/EGFR) inhibitor therapy but must have fully recovered from any skin toxicities prior to registration
  • Patients must not be planning to receive any of the following concomitant medications that can cause skin rash or other dermatologic reactions that could interfere with the

EGFRI-induced skin toxicity assessments, for the duration of the study: allopurinol;systemic corticosteroids; topical retinoids (Retin-A™, Tretinoin™); or oral retinoids(Amnesteem™, Claravis™, Sotret™)

  • Patients must not be planning to receive concurrent external-beam radiation therapy,including prophylactic cranial radiation
  • Patients may concurrently participate in other therapeutic clinical trials

Locations

  • UC San Diego Moores Cancer Center
    La Jolla California 92093 United States
  • Loma Linda University Medical Center
    Loma Linda California 92354 United States
  • City of Hope Comprehensive Cancer Center
    Duarte California 91010 United States
  • Los Angeles County-USC Medical Center
    Los Angeles California 90033 United States
  • USC / Norris Comprehensive Cancer Center
    Los Angeles California 90033 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Southwest Oncology Group
ID
NCT01416688
Study Type
Observational
Last Updated
December 13, 2017